HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

James G Christensen Selected Research

2- amino- 8- (4- (2- hydroxyethoxy)cyclohexyl)- 6- (6- methoxypyridin- 3- yl)- 4- methylpyrido(2,3- d)pyrimidin- 7(8H)- one

11/2014Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
12/2013Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
8/2012Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.
11/2011PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


James G Christensen Research Topics

Disease

83Neoplasms (Cancer)
10/2022 - 01/2003
17Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
10/2022 - 02/2005
8Neoplasm Metastasis (Metastasis)
01/2019 - 03/2009
7Lung Neoplasms (Lung Cancer)
11/2017 - 05/2008
5Breast Neoplasms (Breast Cancer)
01/2018 - 03/2009
5Glioblastoma (Glioblastoma Multiforme)
04/2012 - 06/2005
5Stomach Neoplasms (Stomach Cancer)
03/2012 - 02/2006
4Colorectal Neoplasms (Colorectal Cancer)
10/2022 - 02/2011
4Carcinoma (Carcinomatosis)
01/2019 - 06/2005
4Neuroblastoma
11/2011 - 05/2008
3Colonic Neoplasms (Colon Cancer)
01/2020 - 07/2011
3Adenocarcinoma
08/2012 - 02/2005
3Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma)
03/2012 - 12/2007
2Fatigue
01/2020 - 04/2013
2Triple Negative Breast Neoplasms
01/2018 - 03/2013
2Melanoma (Melanoma, Malignant)
07/2014 - 03/2009
2Ovarian Neoplasms (Ovarian Cancer)
12/2013 - 01/2010
2Renal Cell Carcinoma (Grawitz Tumor)
08/2013 - 05/2006
2Retinoblastoma (Glioblastoma, Retinal)
08/2013 - 03/2012
2Adenocarcinoma of Lung
06/2013 - 08/2012
2Neuroendocrine Tumors (Neuroendocrine Tumor)
06/2013 - 03/2012
2Disease Progression
04/2013 - 05/2006
2Hypoxia (Hypoxemia)
03/2012 - 10/2007
2Genetic Translocation (Chromosomal Translocation)
05/2008 - 12/2007
2Lymphoma (Lymphomas)
04/2008 - 12/2007
1Brain Neoplasms (Brain Tumor)
01/2022

Drug/Important Bio-Agent (IBA)

26CrizotinibIBA
01/2020 - 05/2007
23Phosphotransferases (Kinase)IBA
01/2015 - 09/2003
12Tyrosine Kinase InhibitorsIBA
01/2019 - 10/2004
12Sunitinib (Sutent)FDA Link
06/2013 - 01/2003
11Proteins (Proteins, Gene)FDA Link
10/2022 - 07/2005
11Anaplastic Lymphoma KinaseIBA
01/2015 - 12/2007
11Proto-Oncogene Proteins c-metIBA
07/2012 - 09/2003
10Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
06/2013 - 11/2003
9Pharmaceutical PreparationsIBA
10/2022 - 02/2006
9ErbB Receptors (EGF Receptor)IBA
10/2012 - 06/2005
95- ((2,6- dichlorobenzyl)sulfonyl)- 3- ((3,5- dimethyl- 4- ((2- (pyrrolidin- 1- ylmethyl)pyrrolidin- 1- yl)carbonyl)- 1H- pyrrol- 2- yl)methylene)- 1,3- dihydro- 2H- indol- 2- oneIBA
02/2011 - 11/2003
8adagrasibIBA
10/2022 - 01/2020
7Biomarkers (Surrogate Marker)IBA
12/2013 - 06/2005
6LigandsIBA
01/2022 - 11/2003
6Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
11/2014 - 07/2005
6Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
11/2011 - 09/2003
42- amino- 8- (4- (2- hydroxyethoxy)cyclohexyl)- 6- (6- methoxypyridin- 3- yl)- 4- methylpyrido(2,3- d)pyrimidin- 7(8H)- oneIBA
11/2014 - 11/2011
4Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
12/2013 - 11/2008
4Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
06/2013 - 06/2005
42- (4- (3- quinolin- 6- ylmethyl- 3H- (1,2,3)triazolo(4,5- b)pyrazin- 5- yl)pyrazol- 1- yl)ethanolIBA
06/2013 - 01/2012
3Tyrosine (L-Tyrosine)FDA Link
01/2018 - 06/2005
3dacomitinibIBA
11/2014 - 02/2012
3Docetaxel (Taxotere)FDA Link
03/2013 - 07/2009
3Lapatinib (GW572016)FDA Link
09/2012 - 02/2012
3Trastuzumab (Herceptin)FDA Link
09/2012 - 07/2005
3Angiogenesis InhibitorsIBA
07/2012 - 10/2007
3tyrosine receptor (receptor, tyrosine)IBA
04/2012 - 05/2006
3Gefitinib (Iressa)FDA Link
02/2012 - 07/2005
3Biological ProductsIBA
11/2010 - 10/2004
3((3Z)- N- (3- chlorophenyl)- 3- ((3,5- dimethyl- 4- ((4- methylpiperazin- 1- yl)carbonyl)- 1H- pyrrol- 2- yl)methylene)- N- methyl- 2- oxo- 2,3- dihydro- 1H- indole- 5- sulfonamide)IBA
04/2009 - 09/2003
2PlatinumIBA
01/2022 - 12/2013
2Glycine (Aminoacetic Acid)FDA LinkGeneric
01/2021 - 06/2013
2Codon (Codons)IBA
01/2021 - 06/2013
2Histone Deacetylases (Histone Deacetylase)IBA
01/2019 - 01/2018
2mocetinostatIBA
01/2019 - 01/2018
2Erlotinib Hydrochloride (CP 358,774)FDA Link
10/2016 - 11/2011
2Sirolimus (Rapamycin)FDA Link
11/2014 - 03/2005
2palbociclibIBA
07/2014 - 08/2013
2figitumumabIBA
12/2013 - 07/2011
2Insulin-Like PeptidesIBA
12/2013 - 03/2012
2mirdametinibIBA
12/2013 - 08/2012
2Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
12/2013 - 02/2012
2nirogacestatIBA
03/2013 - 09/2012
2Amyloid Precursor Protein Secretases (beta-Secretase)IBA
03/2013 - 09/2012
2AfatinibIBA
10/2012 - 02/2012
2Messenger RNA (mRNA)IBA
09/2012 - 06/2005
2Small Interfering RNA (siRNA)IBA
04/2012 - 02/2005
2Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
04/2012 - 04/2012
2N- (2- (6- (4- cyclobutylamino- 5- trifluoromethylpyrimidine- 2- ylamino)- 1,2,3,4- tetrahydro- 1,4- epiazano- naphthalen- 9- yl)- 2- oxo- ethyl)acetamideIBA
03/2012 - 04/2010
2Canertinib (CI 1033)IBA
02/2012 - 06/2005
2Phosphatidylinositols (Phosphatidylinositol)IBA
11/2011 - 11/2008
2Adenosine Triphosphate (ATP)IBA
08/2011 - 11/2003
2Semaphorins (Semaphorin)IBA
04/2009 - 02/2005
2Growth Factor ReceptorsIBA
11/2008 - 02/2006
2Imatinib Mesylate (Gleevec)FDA Link
05/2006 - 07/2005
2Mesylates (Mesylate)IBA
05/2006 - 06/2005
1symmetric dimethylarginineIBA
10/2022
1KRASG12D inhibitor MRTX1133IBA
01/2022
1B7-H1 AntigenIBA
01/2022
1Cysteine (L-Cysteine)FDA Link
01/2021
1sotorasibIBA
01/2021
1serum P-component (CIt)IBA
01/2021
1Blood Proteins (Serum Proteins)IBA
01/2021
1RNA (Ribonucleic Acid)IBA
01/2021
1Alanine Transaminase (SGPT)IBA
01/2020
1Carrier Proteins (Binding Protein)IBA
01/2019
1sitravatinibIBA
01/2019
1Histone Deacetylase InhibitorsIBA
01/2019
1AcetyltransferasesIBA
01/2019
1CREB-Binding ProteinIBA
01/2019
1Histone Acetyltransferases (Histone Acetyltransferase)IBA
01/2019

Therapy/Procedure

36Therapeutics
01/2022 - 01/2003
4Oral Administration
10/2022 - 06/2005
4Drug Therapy (Chemotherapy)
01/2022 - 02/2012